XTL Biopharmaceuticals Ltd. stock is up 24.1% since 30 days ago. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.84% of the previous 18 December’s closed higher than November.
The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. is headquartered in Ramat Gan, Israel.